Septerna
A US biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs) that was launched in January 2022 with a Series A financing of $100 million.
Septerna has an emerging pipeline of GPCR-targeted small molecule drug discovery programs, along with growth potential to reach many GPCRs that have been undruggable and unexploited to date.
The Series A financing was led by Third Rock Ventures with significant support by Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital and Logos Capital.
Latest Septerna News & Features
13 September 2023
27 January 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze